J&J Slammed With $417 Million Verdict in California Talc Cancer Trial
The trial lasted four weeks and deliberation took two days.

Johnson & Johnson (JNJ) got hit with a $417 million verdict Monday in the first California trial evaluating an alleged link between the company's talcum powder products and ovarian cancer, Law360 reported.

The California jury set a new standard in the string of suits alleging J&J's talc products caused a woman's terminal cancer, setting a higher verdict amount than Missouri juries did.

After a four-week trial and two days of deliberation, the Los Angeles jury found Johnson & Johnson failed to warn plaintiff Eva Echeverria of the increased risk of ovarian cancer associated with use of the company's talcum products.

J&J stock traded slightly up 0.6% to $133.40 mid-afternoon Monday.

More of What's Trending on TheStreet:

More from Stocks

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Will Tesla Stock Tumble 33% to $195?

Will Tesla Stock Tumble 33% to $195?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Is Best Buy Sleeping With the Enemy With Amazon Partnership?

Video: The S&P 500 Is Failing to Make New Highs

Video: The S&P 500 Is Failing to Make New Highs

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump

Dow, S&P 500 and Nasdaq Finish Lower as Apple, P&G Slump